Oncovista Innovative Therapies Inc · OTC:OVIT
Oncovista Innovative Therapies — Aviation Upgrade Technologies — Investor Presentation (October 2007)
40 slides from Oncovista Innovative Therapies's investor presentation, Oct 29, 2007
Slide 1: Company Overview
Company Overview October 2007 0
Slide 2: Safe Harbor Statement
Safe Harbor Statement Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketpl
Slide 3: Contents
Contents Corporate Mission Background, Highlights and History Cancer Market Overview and The Opportunity Business Strategy FDA Strategy Out-Licensing Strategy Our Pipeline and Portfolio Projected Milestones IP Position Investment Summary Financing History The Team - Management and Clinical Advisory
Slide 4: Paradigms in Cancer Treatment
Paradigms in Cancer Treatment Efficacy Typically, response rates to chemotherapeutic regimens is low (20-40%). Frequently, patients who initially respond will relapse and be refractory to regimens that had previously been effective Patients often experience progressively shorter periods of remission
Slide 5: Corporate Mission
Corporate Mission OncoVista’s mission is the development and rapid commercialization of innovative targeted therapies for safe and efficacious treatment of cancer, by utilizing biomarkers to extend, and improve the quality of life. 4
Slide 6: Background, Highlights and History
Background, Highlights and History 2004 Formation of OncoVista as a Delaware Corporation and in-licensing of L-nucleoside conjugate and tubulin isotype-specific anti-mitotic technologies 2005 Acquisition of controlling interest (51%) in a German company (AdnaGen AG) which developed, and is selling,
Slide 7: Cancer Market Overview - Incidence & Treatment
Cancer Market Overview - Incidence & Treatment Cancer is the second leading cause of death in the US after heart disease and, according to the American Cancer Society, 559,650 people will die from cancer in the US in 2007 (1,500 per day) Cancer is a leading cause of death worldwide. According to WHO
Slide 8: Business Strategy
Business Strategy A Focused In-licensing / Acquisition Program for Drugs in Clinical Trials A Practical, Rational Approach to Drug Development A Disciplined Internal Development Strategy for Therapeutic Drugs An Integrated Diagnostics Platform 7
Slide 9: FDA Strategy
FDA Strategy The Company has substantial expertise and extensive experience in all matters pertaining to regulatory approval In order to minimize the time required to obtain approval for its drugs, OncoVista intends to take advantage of: Rolling NDA Submissions – drug application, where each section
Slide 10: Out-Licensing Strategy
Out-Licensing Strategy Upon reaching an advanced clinical stage in drug development, the Company anticipates entering into strategic and/or marketing relationships with a third-party which has: Significant marketplace presence Substantial sales force calling on oncologists These relationships would
Slide 11: Our Pipeline
Our Pipeline A focus on registration efficiency through accelerated approval and / or orphan status Phase I Phase II Phase III Launched Pre-Clinical AdnaGen Oncology Diagnostics* Cordycepin (OVI-123) L-Nucleoside conjugate (OVI-117) Anti-mitotic compound *Marketed in Europe; Seeking FDA approval in
Slide 12: Our Pipeline
Our Pipeline AdnaGen AG Detection of circulating tumor cells (CTCs; markers of metastatic disease) in blood; CTCs have prognostic value and provide molecular profile of tumor metastases Status: kits for metastatic breast and colon cancer marketed in Europe; studies on-going in the US directed at obt
Slide 13: Our Pipeline
Our Pipeline L-Nucleoside conjugate (OVI-117) Late preclinical stage drug active in vivo: colon, breast and prostate cancer models, with significantly reduced toxicity Status: pre-IND; in GLP animal safety studies Market Potential: >$1B Tubulin-Isotype Specific Anti-Mitotics Preclinical stage develo
Slide 14: Potential Milestones
Potential Milestones 4Q07 1Q08 2Q08 3Q08 4Q08 1Q09 2Q09 3Q09 4Q09 1Q10 2Q10 Initiate Phase I/II Cordycepin trial Decide on exercise of AdnaGen option Identify lead tubulin isotype anti-mitotic compounds Submit IND for Phase I of OVI-117 in Colorectal Acquire next Phase II in-license Interim assessme
Slide 15: IP Position
IP Position 12 issued US and foreign patents In excess of two dozen applications filed in the U.S. and abroad Note list of patents & applications in the “Supplemental Slides” 14
Slide 16: Investment Summary
Investment Summary Total market potential greater than $3.5 billion A seasoned founding team with a proven track record of anticancer drug development and registration An experienced, committed and involved clinical advisory board Demonstrated expertise in acquisitions / mergers and in-licensing A c
Slide 17: Financing History
Financing History The Company has funded its operations primarily through proceeds from the sale of: $0.6 million in common stock in start-up financing in 2004 - Round “A” $4.4 million in common stock in 2005 (some carried over into 2006) - Round “B1” $1.9 million in common stock in 2006 - Round “B2
Slide 18: The Team – Management
The Team – Management Alexander L. Weis, Ph.D.: Chairman, CEO & President Principal founder of OncoVista, Inc. Previous Experience 1994-1998: Co-founder of ILEX Oncology, Chief Scientific Officer and Executive VP Earlier: Lipitek International, Vector Therapeutics, MykoBiologics, Cancer Therapy and
Slide 19: The Team - Clinical Advisory Board
The Team - Clinical Advisory Board Eric Rowinsky, M.D. (Chairman) Randall K. Johnson, Ph.D. Senior VP and Chief Medical Officer at Expert in Translational Research ImClone Systems, Inc. Senior positions at GSK and NCI Key roles in the development of Taxol®, Hycamtin® and many other anticancer Allan
Slide 20: The Team – Board of Directors
The Team – Board of Directors Alexander L. Weis, Ph.D. – Chairman, CEO Corey Levenson, Ph.D. - CTO William Brock – Director Alexander Ruckdaeschel – Director Jim Wemett – Director 19
Slide 21: OncoVista, Inc.
OncoVista, Inc. 14785 Omicron Drive Suite 104 San Antonio, TX 78245-3222 http://www.oncovista.com 20
Slide 22: Supplemental Slides
Confidential Supplemental Slides October 2007 21
Slide 23: Safe Harbor Statement
Safe Harbor Statement Certain matters discussed in this press release are “forward-looking statements” intended to qualify for the safe harbors from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketpl
Slide 24: Contents
Contents Our Portfolio Cordycepin (OVI-123) AdnaGen Oncology Diagnostics L-Nucleoside Conjugates (OVI-117) Tubulin-Isotype Specific Anti-Mitotics Patents 23
Slide 25: Our Portfolio – Cordycepin (OVI-123) Overview
Our Portfolio – Cordycepin (OVI-123) Overview Profile Cordycepin (3’-deoxyadenosine) is a nucleoside analog which is selectively toxic to cells which express the enzyme terminal deoxynucleotidyl transferase (TdT) Nearly all acute lymphoblastic leukemia (ALL) patients are TdT-positive as are some acu
Slide 26: Phase I/II Trial for Registration of Cordycepin
Phase I/II Trial for Registration of Cordycepin Patients (ALL, AML and CML) will be treated with a combination of Cordycepin and Pentostatin (an ADA inhibitor) Patients with Refractory TdT- Phase I Phase II Endpoint FDA Meeting Positive ALL, AML Request SPA CR n=up to 18 n=up to100 1. & CML Indicati
Slide 27: Our Portfolio – Cordycepin Market Potential
Our Portfolio – Cordycepin Market Potential In 2006 in the US: 35,000 new leukemia cases, 200,000 individuals living with or in remission from leukemia, annual morbidity rate of 23,000 Cordycepin is a treatment for leukemia patients that are refractory to chemotherapeutics or have experienced a rela
Slide 28: Cordycepin - Summary
Cordycepin - Summary A Phase I clinical-stage drug Active against TdT-positive leukemias Status: Phase I/II clinical trial; Orphan Drug Designation obtained IP: Patent protection through 2014; next generation analogs: 2023; should also be eligible for orphan drug designation Budget and Timeline: $3.
Slide 29: Our Portfolio - AdnaGen Oncology Diagnostics
Our Portfolio - AdnaGen Oncology Diagnostics Early detection of metastatic CTC can mean the difference between life and death Current treatment decisions often based on subjective and qualitative information Ability to detect tumor markers quantitatively would improve treatment process in two ways:
Slide 30: AdnaGen AG - Summary
AdnaGen AG - Summary Detection of circulating tumor cells (CTCs; markers of metastatic disease) in blood CTCs have prognostic value and provide molecular profile of tumor metastases Status: kits for metastatic breast and colon cancer marketed in Europe; studies on-going in the US directed at obtaini
Slide 31: Our Portfolio - L-Nucleoside Conjugates (OVI-117)
Our Portfolio - L-Nucleoside Conjugates (OVI-117) Colorectal cancer is the third most common form of cancer For 2006: 145,000 new colorectal cancer cases of which colon cancer accounts for 105,000; colorectal cancer caused 56,000 deaths While colon cancer has 90% curative rate at an early stage dete
Slide 32: Our Portfolio - L-Nucleoside Conjugates (Cont’d)
Our Portfolio - L-Nucleoside Conjugates (Cont’d) This graph shows the ability of OVI-117 to inhibit growth of human colon tumor (HT-29) xenograft growing in a mouse model 31
Slide 33: L-Nucleoside Conjugate - Summary
L-Nucleoside Conjugate - Summary Late preclinical stage drug – lead candidate: OVI-117 Active in vivo: colon, breast and prostate cancer models, with reduced toxicity Status: final stage preclinical IP: Patent protection through 2019 Development Plan: complete GLP toxicology studies and file IND Bud
Slide 34: Tubulin-Isotype Specific Anti-Mitotics - Summary
Tubulin-Isotype Specific Anti-Mitotics - Summary Preclinical stage development program – molecular modeling, synthesis and biochemical screening Tubulin isotype selectivity seen in binding assays Status: lead evaluation and selection is on-going IP: Multiple US and international patent applications
Slide 35: Patents
Patents |. Portfolio Rated to Corcheepin Therapeutic method for selectively treating |terminal decoynucle otidyl transferase positive neoplastic leukemias and lymphomas Methods for the treatment and prevention 5,679,648 of fungal infections by administ ation of 3- 4.907.818 de oxypurine nucleosides
Slide 36: Patents (Cont’d)
Patents (Cont’d) III. L-Nucleoside Patent Portfolio Invention Inventors Appl N o Filing Date Water-Soluble Compound Tuszynski, Greenwald, Curry, Goss 10/923,615 20-Aug-04 Process for Treating a Biological Organism Tuszynski, Greenwald, Curry, Goss 10/976,274 28-Oct-04 Water-Soluble Compound Tuszynsk
Slide 37: Patents (Cont’d)
Patents (Cont'd) VV. AdnaGen Patert Portfolio - Techndlogies |Amplitcation | Oligonucleotide Cont gurati IDE 10159904 |DNAAraythat enrichesthe probe to be | Filed 6-Dec-01 Array Method fr Oligonucleotide detected b yrepetitive hybridization and/or Detection and Apparatus MWO.03048385 reduces the bac
Slide 38: Patents (Cont’d)
Patents (Cont’d) VII. AdnaGen Patent Portfolio Tumor Diagnostics A4
Slide 39: Patents (Cont’d)
Patents (Cont'd) VIIL AdnaGen Patent Portfolio - Prenatal Diagnostics Mild Enrichment of Fetal Cells from Peripheral Blood and Use [Thereof DE 100 36 433 ‘wWO0208751 The invention relates to a method for highly enriching fetal cells as products lusing antibodies: arti-w, anti-r, anti-| and andi-| pl
Slide 40: OncoVista, Inc.
OncoVista, Inc. 14785 Omicron Drive Suite 104 San Antonio, TX 78245-3222 http://www.oncovista.com
Aviation Upgrade Technologies — Investor Presentation (October 2007) on 6ix